| TUMOR TYPE | CANCER SUBTYPE | TYPE OF CLASSIFIER | TYPE OF THERAPY | MAIN TARGET | DISCOVERY | PROTOTYPE ASSAY | ANALITYCAL VALIDATION | CLINICAL VALIDATION | REGULATORY APPROVAL |
|---|---|---|---|---|---|---|---|---|---|
| BREAST | HR+ HER- | prognostic | hormonal / chemotherapy | ||||||
| predictive | targeted therapy | CDK4/6 | |||||||
| predictive | targeted therapy | PIK3CA | |||||||
| predictive | targeted therapy | ATR | |||||||
| predictive | targeted therapy | PARP | |||||||
| TNBC | prognostic | chemotherapy | |||||||
| predictive | targeted therapy | TROP-2 | |||||||
| HER2+ | predictive | targeted therapy | HER2 | ||||||
| OVARIAN | HGSC | predictive | targeted therapy | PARP | |||||
| PANCREATIC | PDAC | prognostic | chemotherapy | ||||||
| predictive | targeted therapy | PARP | |||||||
| LUNG | NSCCL | predictive | immunotherapy | PD-1 / PD-L1 | |||||
| predictive | targeted therapy | EGFR | |||||||
| predictive | targeted therapy | ALK | |||||||
Biomarker discovery pipeline
TUMOR TYPE: BREAST
CANCER SUBTYPE: HR+ HER-
CLASSIFIER: prognostic
THERAPY: hormonal / chemotherapy
CLASSIFIER: predictive
THERAPY: targeted
CLASSIFIER: predictive
THERAPY: targeted
CLASSIFIER: predictive
THERAPY: targeted
CLASSIFIER: predictive
THERAPY: targeted
CANCER SUBTYPE: TNBC
CLASSIFIER: prognostic
THERAPY: chemotherapy
CLASSIFIER: predictive
THERAPY: targeted
CANCER SUBTYPE: HER2+
CLASSIFIER: predictive
THERAPY: targeted
TUMOR TYPE: OVARIAN
CANCER SUBTYPE: HGSC
CLASSIFIER: predictive
THERAPY: targeted
TUMOR TYPE: PANCREATIC
CANCER SUBTYPE: PDAC
CLASSIFIER: prognostic
THERAPY: chemotherapy
CLASSIFIER: predictive
THERAPY: targeted
TUMOR TYPE: LUNG
CANCER SUBTYPE: NSCCL
CLASSIFIER: predictive
THERAPY: immunotherapy
CLASSIFIER: predictive
THERAPY: targeted
CLASSIFIER: predictive
THERAPY: targeted
TECHNICAL NOTES
Read our technotes to learn how we constructed the genomic classifiers – from whole-genome data mining, feature extraction and engineering, through AI model development and retrospective validation.
_ALICE
A stratification classifier for CARBOPLATIN/PARP INHIBITION THERAPY that broadens standard HRD diagnostic testing by additional 44 genomic biomarkers.
Download
CDK4/6iDx
The first, multi-biomarker test FOR SELECTING RESPONDERS TO CDK4/6 INHIBITOR THERAPY in HR+/HER2- breast cancer.
Download